News about Global Pharma

Lupin Acquires VISUfarma, Strengthens Global Specialty Ophthalmology Business

By integrating VISUfarma’s established commercial operations, Lupin aims to tap into the attractive ophthalmology market.

Global Pharma | 30/09/2025 | By Dineshwori |  192

USA Tariff Policy Puts USD 3.1 Billion of Singapore Pharma Exports at Risk Amid Ongoing Talks

The USA’s new tariff policy threatens approximately USD 3.1 billion worth of Singapore’s pharmaceutical exports, according to Singaporean authorities, with trade discussions between the two nations currently underway.

Global Pharma | 29/09/2025 | By Darshana |  308

Dr. Reddy's, Hetero to Produce Affordable Generic Lenacapavir For HIV Prevention by 2027

Indian pharmaceutical companies Dr. Reddy’s Laboratories and Hetero Labs (Hetero) have signed landmark agreements to manufacture generic versions of lenacapavir, a revolutionary long-acting HIV prevention drug, which will be available at roughly USD 40 per patient per year in low- and middle-income countries (LMICs) starting in 2027.

Global Pharma | 29/09/2025 | By Dineshwori |  644

Copan Diagnostics Invests USD 7 Million to Expand US Manufacturing Footprint

Copan Diagnostics, part of the privately held Italy-based Copan Group, has announced more than USD 7 million in new US manufacturing investments across its facilities in California and Puerto Rico.

Global Pharma | 25/09/2025 | By Dineshwori |  288

US FDA Grants Priority Review for Enhertu + Pertuzumab in HER2+ Metastatic Breast Cancer

The US FDA has granted Priority Review to Enhertu + Pertuzumab for HER2+ metastatic breast cancer, following DESTINY-Breast09 trial results showing a 44 percent reduction in risk of disease progression or death and over three years’ median Progression-Free Survival (PFS), positioning it as a potential new first-line standard of care.

Global Pharma | 25/09/2025 | By Dineshwori |  165

Alembic Wins USFDA Clearance for Paroxetine ER Tablets for Depression and Anxiety Disorders

Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg.

Global Pharma | 25/09/2025 | By Dineshwori |  178

Lupin Receives Tentative Approval from US FDA for its HIV treatment tablets

Lupin has received tentative US FDA approval for Bictegravir, Emtricitabine and Tenofovir Alafenamide Tablets to treat HIV, bioequivalent to Gilead’s Biktarvy, for adults and paediatric patients over 25 kg.

Global Pharma | 25/09/2025 | By Dineshwori |  221

US FDA Declines Approval for Biogen's Higher-Dose Spinraza in SMA

The decision was relayed via a ‘complete response letter’ to Biogen, which clarified there were no issues with the clinical data behind the new high-dose regimen. Biogen says it will resubmit the application promptly, drawing on information that is already at hand.

Global Pharma | 24/09/2025 | By Darshana |  177

Australia Approves Leqembi for Early Alzheimer's Disease Following TGA-Eisai Agreement

The Therapeutic Goods Administration (TGA) of Australia has approved lecanemab (Leqembi), developed collaboratively by BioArctic and Eisai, for the treatment of adult patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (early AD).

Global Pharma | 24/09/2025 | By Dineshwori |  167

Palatin Receives USD 6.5M Milestone Payment Under Retinal Disease Collaboration with Boehringer Ingelheim

Palatin Technologies, the US-based biopharmaceutical company focused on developing medicines that modulate the melanocortin receptor system, announced it has achieved a research milestone under its collaboration with Boehringer Ingelheim, triggering a 6.5 million payment to the company.

Global Pharma | 23/09/2025 | By Dineshwori |  148